Shopping Cart
- Remove All
- Your shopping cart is currently empty
AZD6280 is a novel, subtype-selective GABAAα2/3 receptor positive modulators, used for treatment of generalized anxiety disorder.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $239 | In Stock | |
5 mg | $488 | In Stock | |
10 mg | $712 | In Stock | |
25 mg | $1,130 | In Stock | |
50 mg | $1,580 | In Stock | |
100 mg | $2,150 | In Stock | |
1 mL x 10 mM (in DMSO) | $537 | In Stock |
Description | AZD6280 is a novel, subtype-selective GABAAα2/3 receptor positive modulators, used for treatment of generalized anxiety disorder. |
In vivo | The [11C]flumazenil binding was reduced in a dose-dependent, saturable manner by AZD6280. Maximum receptor occupancy could be reached for AZD6280 without causing sedation or cognitive impairment. The K i,plasma estimates for AZD6280 was 440 nmol/l[1]. |
Animal Research | Two PET studies, using high-resolution research tomography (HRRT) and the radioligand [11C]flumazenil, were performed in 12 subjects at baseline and after administration of single oral doses of AZD7325 (0.2 to 30 mg) and AZD6280 (5 to 40 mg). PET images were analyzed using a simplified reference tissue model, and regional binding potentials (BPND) were obtained. The relationship between plasma concentration of AZD7325 or AZD6280 and GABAA receptor occupancy was described by hyperbolic function, and K i,plasma (plasma concentration required for 50% receptor occupancy) was estimated. Assessments of safety and tolerability included recording of adverse events, vital signs, electrocardiogram, and laboratory tests[1]. |
Molecular Weight | 366.41 |
Formula | C20H22N4O3 |
Cas No. | 942436-93-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 25 mg/mL (68.23 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.